Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ibafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | TOP2A | P11388 | 8/20 | 0.51 |
| ▸ | TOP2B | Q02880 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TUBB | P07437 | 1/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibafloxacin SCHEMBL154637 | 1.00 | LMNA (0.69) | LMNAKDM4ESMN1; SMN2CYP1A2TOP2A | |
| Ibafloxacin SCHEMBL29465687 | 1.00 | LMNA (0.69) | LMNAKDM4ESMN1; SMN2CYP1A2TOP2A | |
| SCHEMBL8083425 | 0.89 | LMNA (0.70) | LMNAKDM4ESMN1; SMN2CYP1A2TOP2A | |
| SCHEMBL10841687 | 0.88 | LMNA (0.69) | LMNAKDM4ESMN1; SMN2CYP1A2TOP2A | |
| SCHEMBL16518639 | 0.88 | KDM4E (0.61) | LMNAKDM4ESMN1; SMN2CYP1A2TOP2A | |
| SCHEMBL10784346 | 0.87 | LMNA (0.68) | LMNAKDM4ESMN1; SMN2CYP1A2TOP2A | |
| Water SCHEMBL10842574 | 0.87 | LMNA (0.68) | LMNAKDM4ESMN1; SMN2CYP1A2TOP2A | |
| SCHEMBL10782548 | 0.87 | LMNA (0.68) | LMNAKDM4ESMN1; SMN2CYP1A2TOP2A | |
| SCHEMBL10785119 | 0.87 | LMNA (0.68) | LMNAKDM4ESMN1; SMN2CYP1A2TOP2A | |
| Water SCHEMBL10788704 | 0.86 | LMNA (0.67) | LMNAKDM4ESMN1; SMN2CYP1A2TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2293778-B1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND MOMETASONE | INTERVET INT BV (NL) | 2013-09-18 | — | — | EP | disclosed |
| EP-2540715-A1 | Fused substituted aminopyrrolidine derivative | Daiichi Sankyo Company, Limited (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INC. | 2012-02-23 | — | — | US | disclosed |
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INC. | 2012-02-23 | — | — | US | disclosed |
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL BV | 2010-04-08 | — | — | US | disclosed |
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL BV | 2010-04-08 | — | — | US | disclosed |
| WO-2009147144-A2 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL B.V. (NL) | 2009-12-10 | — | — | WO | disclosed |
| WO-2008082009-A2 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | CYP21A2, CYP27A1, NR3C2 | LMNA 1358/4885KDM4E 3174/4885SMN1; SMN2 4792/4885 |
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | CYP21A2, CYP27A1, NR3C2 | LMNA 1358/4885KDM4E 3174/4885SMN1; SMN2 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.